FDA Open To Behind-The-Counter NDAs While Mulling “Continuum” Class
Executive Summary
FDA is open to behind-the-counter switch applications in which companies propose innovative methods to solve access or selection issues, according to Office of Nonprescription Products staff
You may also be interested in...
FDA Plans Behind-The-Counter Meeting, Mulls “Transitional” Status
FDA will discuss the idea of behind-the-counter drug sales as a possible transitional stage between Rx and OTC status when it holds a forum on the topic with stakeholders
FDA Plans Behind-The-Counter Meeting, Mulls “Transitional” Status
FDA will discuss the idea of behind-the-counter drug sales as a possible transitional stage between Rx and OTC status when it holds a forum on the topic with stakeholders
FDA Approach To Third Drug Class Expected Within Months
FDA will include industry in the process of developing a distribution channel for drugs between the traditional prescription and over-the-counter spaces, agency representatives said at the Consumer Healthcare Products Association's Regulatory and Scientific Conference